WebMar 14, 2024 · WILMINGTON, Del.--(BUSINESS WIRE)--Mar. 14, 2024-- Incyte(Nasdaq:INCY) today announced that multiple abstracts from across its oncology portfolio will be presented during the upcoming American Association for Cancer Research(AACR) Annual Meeting 2024, held April 14-19, in Orlando, Florida. WebIncyte is a global biopharmaceutical company that is focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization …
A patent review of anticancer CDK2 inhibitors (2024-present)
WebSep 25, 2024 · Assignee: Incyte Corporation Inventors: Liangxing Wu, Bo Shen, Meizhong Xu, Wenqing Yao Pyrazolopyrimidine compounds and uses thereof Patent number: 11542265 Abstract: Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds. WebA method of treating a human subject having a disease or disorder associated with cyclin-dependent kinase 2 (CDK2), comprising: (i) identifying, in a biological sample obtained … some historical facts about the county glenn
A patent review of anticancer CDK2 inhibitors (2024–present)
WebCDK2 is a member of the CDKs family that plays an important role in regulating the progression of cells into both S- and M-phases of the cell cycle. Studies suggest that … WebCDK2 is of particular interest because deregulation of CDK2 activity occurs frequently in a variety of human cancers. CDK2 plays a crucial role in promoting G1/S transition and S phase progression. WebDiscovery of INCB123667, a potent and selective cyclin-dependent kinase 2 (CDK2) inhibitor for the treatment of cyclin E dysregulated cancers (AACR-NCI-EORTC 2024) - "Our data … some himalayan residents